Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination

The U.S. Food and Drug Administration (FDA) recently issued an Emergency Use Authorization (EUA) for two highly effective Sars-CoV-2 (COVID-19) vaccines from Pfizer-BioNTech and Moderna. More recently, EUA was granted for the Johnson and Johnson COVID-19 vaccine which uses traditional virus-based te...

Descripción completa

Detalles Bibliográficos
Autores principales: Yocum, Andrew, Simon, Erin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095021/
https://www.ncbi.nlm.nih.gov/pubmed/33980419
http://dx.doi.org/10.1016/j.ajem.2021.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095021/
https://www.ncbi.nlm.nih.gov/pubmed/33980419
http://dx.doi.org/10.1016/j.ajem.2021.05.001

Ejemplares similares